Clinical Evaluation of Two Daily Disposable Toric Soft Contact Lenses Over One Week of Wear
Study Details
Study Description
Brief Summary
This is a bilateral wear, dispensing, randomized, controlled, double-masked, 2-sequence ×2-period crossover study to evaluate ocular physiology following contact lens wear.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: TEST/CONTROL Eligible subjects that are habitual contact lens wearers will be randomized into the (TEST/CONTROL) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period. |
Device: PRECISION1® for Astigmatism Contact Lenses
TEST
Device: MyDay® Toric Soft Contact Lenses
CONTROL
|
| Experimental: CONTROL/TEST Eligible subjects that are habitual contact lens wearers will be randomized into the (CONTROL/TEST) sequence and will wear two different study lenses one at a time over the two wear periods. During each wear period the lenses will be worn bilaterally for approximately 1 week. Study lenses will be worn for a minimum of 8 hours per day and at least 5 days per week during the wear period. |
Device: PRECISION1® for Astigmatism Contact Lenses
TEST
Device: MyDay® Toric Soft Contact Lenses
CONTROL
|
Outcome Measures
Primary Outcome Measures
- Slit Lamp Findings [Up to one week follow-up]
Slit Lamp Findings (Grade 3 or higher) will be assessed for each subject eye at all study visits (schedule and unscheduled). SLFs will be evaluated and classified using the FDA Grading scale rating from 0 to 4, where Grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1=trace, Grade 2= mild, Grade 3=moderate and Grade 4= severe). The percentage of eyes with Grade 3 or higher slit lamp findings will be analyzed and will include corneal infiltrates.
Eligibility Criteria
Criteria
Inclusion Criteria:
Potential subjects must satisfy of all the following criteria to be enrolled in the study.
The subject must:
-
Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
-
Appear able and willing to adhere to the instructions set forth in this clinical protocol.
-
Be between 18 and 39 (inclusive) years of age at the time of screening.
-
By self-report, habitually wear soft contact lenses in both eyes in a daily reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual wear is defined as a minimum of 6 hours of wear per day, for a minimum of 2 days per week during the past month.
-
Possess a wearable pair of spectacles that provide correction for distance vision. Inclusion Criteria at Baseline Evaluation
The subject must:
-
Have the spherical component of their vertex-corrected distance refraction must be between -0.875 to -4.625 DS (inclusive) in each eye.
-
Have the magnitude of the cylindrical component of their vertex-corrected distance refraction between 0.625 DC and 1.625 DC in both eyes.
-
Have the cylinder axis of their distance refraction between 165° and 15° (i.e., 180±15°, inclusive) or between 75° and 105° (i.e., 90±15°, inclusive) in each eye.
-
Have best corrected monocular distance visual acuity of 20/30 or better in each eye.
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
The subject must not:
-
Be currently pregnant or lactating.
-
Be diabetic.
-
Be currently using any ocular medications or have any ocular infection of any type.
-
By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
-
Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
-
Be currently wearing monovision or multifocal contact lenses.
-
Be currently wearing lenses in an extended wear modality.
-
Have a history of strabismus or amblyopia.
-
Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
-
Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment. Exclusion Criteria at Baseline Evaluation
-
Have clinically significant (grade 3 or higher on the FDA grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
-
Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
-
Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | VRC | Jacksonville | Florida | United States | 32256 |
| 2 | Sabal Eye Care | Longwood | Florida | United States | 32779 |
| 3 | Sacco Eye Group | Vestal | New York | United States | 13850 |
| 4 | Professional Vision Care Inc. - Westerville | Westerville | Ohio | United States | 43081 |
| 5 | Botetourt Eyecare LLC | Salem | Virginia | United States | 24153 |
Sponsors and Collaborators
- Johnson & Johnson Vision Care, Inc.
Investigators
- Study Director: Johnson & Johnson Vision Care, Inc. Clinical Trial, Johnson & Johnson Vision Care, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CR-6478